CEO of InSilico Medicine & Deep Longevity. CSO of Biogerontology Research Foundation.
Dr. Zhavoronkov holds two bachelor degrees from Queen’s University, a master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University.
As at Sept-20: 313 Publications, 4,053 Citations
Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and diversity.AI initiative.
Author of "The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy", Palgrave Macmillan, NY, 2013 - available in English, Japanese, Chinese, and Polish.
Visit website: http://www.agelessbook.com/the-author-details/
Alex Zhavoronkov is also referenced in the following:
Latest progress in the molecular, cellular and organismal basis of aging
Alex Zhavoronkov Creations
Alex Zhavoronkov News
Pharma company teams with AI to develop anti aging solutions
Longevity Technology - 15-Oct-2020
Taisho and Insilico collabs to identify novel targets for senolytic drugsRead more...
Alex Zhavoronkov explains why AI can help in peer reviewing drug development research
Nature Biotechnology - 14-Sep-2020
An automated sense-check of publications sounds like a good ideaRead more...
AI reduces drug discovery from years to days - and that's just the start
Singularity Hub - 23-Jul-2020
Insilico Medicine is slashing the cost of drug developmentRead more...
Deep Longevity investors bet on growing need for aging and longevity biomarkers
FierceBiotech - 15-Jul-2020
Biological clocks are a moving target so they'll need other researchers to corroborate their analysisRead more...
Should WHO use a new framework for the diagnosis and treatment of age-related diseases?
Life Extension Advocacy Foundation (LEAF) - 08-May-2020
LEAF summarises and exchange of thoughts between leading aging researchersRead more...
Proposed strategy to protect elderly from gerolavic infections like COVID-19
Forbes - 31-Mar-2020
To benefit long term global health and longevity, and enhance economic recoveryRead more...
Nanalyze looks at Insilico Medicine's AlphaGo moment in pharma
Nanalyze - 09-Oct-2019
From lab to clinic in 2 years instead of 10 would have a huge impact on healthRead more...
Insilico and ARK enter a research collaboration on health-span and longevity
EurekAlert! - 22-May-2019
AI-based methods, to explore mechanisms of ageing and improving health-spanRead more...
Gut microbiome predicts age with 4 year accuracy
Life Extension Advocacy Foundation (LEAF) - 15-Jan-2019
It both affects and is affected by its host statusRead more...